| Dawn Lei, MD | |
|
303 E Army Trail Rd Ste 403, Bloomingdale, IL 60108-2155 | |
| (630) 894-7083 | |
| Not Available |
| Full Name | Dawn Lei |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 9 Years |
| Location | 303 E Army Trail Rd Ste 403, Bloomingdale, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740660554 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 036.146239 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventist Glenoaks | Glendale heights, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Adventist Health Partners Inc | 0244135762 | 211 |
News Archive
RetroSense Therapeutics, LLC, a Michigan-based company, announced that it has executed its exclusive, worldwide option and signed a license agreement for novel gene-therapy approaches for treating blindness developed at Wayne State University's School of Medicine.
The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over diclofenac/hyaluronic acid gel. Such an added benefit cannot be derived from the dossier, however, as the drug manufacturer did not submit any relevant data: it did not cite any studies that directly compared ingenol mebutate with diclofenac/hyaluronic acid gel, and the method chosen by the manufacturer for an indirect comparison was unsuitable.
While most of the public favors the Obama administration's contraception compromise, the Catholic bishops will launch TV and radio ads against the mandate.
The researchers reviewed 72 randomized trials and 9,991 patients who had chronic hepatitis C for more than six months and were previously untreated, who had relapsed after treatment or who had not responded to other treatment.
› Verified 9 days ago
| Entity Name | Adventist Health Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033490651 PECOS PAC ID: 0244135762 Enrollment ID: O20040127000064 |
News Archive
RetroSense Therapeutics, LLC, a Michigan-based company, announced that it has executed its exclusive, worldwide option and signed a license agreement for novel gene-therapy approaches for treating blindness developed at Wayne State University's School of Medicine.
The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over diclofenac/hyaluronic acid gel. Such an added benefit cannot be derived from the dossier, however, as the drug manufacturer did not submit any relevant data: it did not cite any studies that directly compared ingenol mebutate with diclofenac/hyaluronic acid gel, and the method chosen by the manufacturer for an indirect comparison was unsuitable.
While most of the public favors the Obama administration's contraception compromise, the Catholic bishops will launch TV and radio ads against the mandate.
The researchers reviewed 72 randomized trials and 9,991 patients who had chronic hepatitis C for more than six months and were previously untreated, who had relapsed after treatment or who had not responded to other treatment.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dawn Lei, MD 303 E Army Trail Rd Ste 403, Bloomingdale, IL 60108-2155 Ph: (630) 894-7083 | Dawn Lei, MD 303 E Army Trail Rd Ste 403, Bloomingdale, IL 60108-2155 Ph: (630) 894-7083 |
News Archive
RetroSense Therapeutics, LLC, a Michigan-based company, announced that it has executed its exclusive, worldwide option and signed a license agreement for novel gene-therapy approaches for treating blindness developed at Wayne State University's School of Medicine.
The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over diclofenac/hyaluronic acid gel. Such an added benefit cannot be derived from the dossier, however, as the drug manufacturer did not submit any relevant data: it did not cite any studies that directly compared ingenol mebutate with diclofenac/hyaluronic acid gel, and the method chosen by the manufacturer for an indirect comparison was unsuitable.
While most of the public favors the Obama administration's contraception compromise, the Catholic bishops will launch TV and radio ads against the mandate.
The researchers reviewed 72 randomized trials and 9,991 patients who had chronic hepatitis C for more than six months and were previously untreated, who had relapsed after treatment or who had not responded to other treatment.
› Verified 9 days ago
Dr. Greg Edward Sharon, M.D., Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 303 E Army Trail Rd, Ste # 403, Bloomingdale, IL 60108 Phone: 630-894-7083 Fax: 630-894-9472 |